Last reviewed · How we verify
HS-10241+ Almonertinib
HS-10241 is a third-generation EGFR tyrosine kinase inhibitor designed to target EGFR mutations including common and uncommon variants, often combined with almonertinib (a third-generation EGFR-TKI) to enhance efficacy against resistant lung cancers.
HS-10241 is a third-generation EGFR tyrosine kinase inhibitor designed to target EGFR mutations including common and uncommon variants, often combined with almonertinib (a third-generation EGFR-TKI) to enhance efficacy against resistant lung cancers. Used for Non-small cell lung cancer with EGFR mutations (Phase 3 development).
At a glance
| Generic name | HS-10241+ Almonertinib |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor (third-generation) |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HS-10241 selectively inhibits mutant EGFR while sparing wild-type EGFR, addressing resistance mechanisms that emerge during treatment with earlier-generation inhibitors. The combination with almonertinib targets multiple EGFR pathways and resistance mutations, particularly in non-small cell lung cancer with EGFR sensitizing mutations. This dual-targeting approach aims to overcome acquired resistance and improve progression-free survival.
Approved indications
- Non-small cell lung cancer with EGFR mutations (Phase 3 development)
Common side effects
- Diarrhea
- Rash
- Nausea
- Fatigue
Key clinical trials
- A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy (PHASE3)
- Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10241+ Almonertinib CI brief — competitive landscape report
- HS-10241+ Almonertinib updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI